Vera Therapeutics (VERA) Rises on Strong Phase 3 IgAN Data and FDA Submission—Is Regulatory Execution the Next Key Hurdle?

Vera Therapeutics recently announced positive results from its Phase 3 ORIGIN trial of atacicept in adults with immunoglobulin A nephropathy (IgAN), highlighting a 42% reduction in proteinuria ...

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans

Mineralys Therapeutics recently presented positive Phase 3 clinical data for lorundrostat at ASN Kidney Week 2025, revealing significant reductions in blood pressure and albuminuria among patients ...

Global study finds stable acute kidney injury mortality with shifting age patterns

A five-year study has revealed a stability in global acute kidney injury (AKI)–related mortality rates with differing patterns that indicate a rising concentration of mortality in older populations ...
Healio

Advancing equity in nephrology requires collaboration, readiness to address disparities

Implementing policy change to advance equity in kidney care requires interdisciplinary support and institutional readiness, ...

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the ...

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: ...

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.